IMCPL / Flow Cytometry

该实验室是匹兹堡大学癌症研究所(UPCI)的专门设施， 致力于治疗前、治疗中和治疗后免疫反应的最新评估 癌症患者的干预措施。它还生产用于人类治疗的细胞产品。在它的角色中 作为该计划项目的核心，IMCPL将承担支持以生物疗法为基础的 所有四个项目都提出了临床试验。核心，作为一个GMP机构，将培养和表征 用于患者治疗的树突状细胞(DC)，并通过用多肽或蛋白质脉冲这些DC来制备疫苗。 Core将负责DC疫苗的质量和无菌。它还将采购和加工 在与本计划项目相关的临床试验过程中采集的所有体液和组织。 核心将通过执行ELISPOT分析来监测对接种疫苗的免疫反应， 四聚体分析或细胞因子流式细胞术。上清液或体液中的细胞因子 通过基于免疫微球的多重方法进行监测。核心还将准备协助该计划 项目调查员在实施评估免疫应答所需的分析方面的作用 疫苗。核心将确保其生成的所有蜂窝产品和收集的样本 附上适当的文件，以便将实验室分析与临床结果联系起来。 该中心还将协助准备IND提交的材料。核心实验室有很长一段时间 与所有调查人员的合作历史，以及在本计划项目的背景下，将完全 致力于支持头颈部癌、黑色素瘤或肾细胞癌患者的临床试验 癌症。

This laboratory is a specialized facility at the University of Pittsburgh Cancer Institute (UPCI), which is dedicated to the state-of-the-art evaluation of immune responses prior to, during and after therapeutic interventions in patients with cancer. It also generates cellular products for human therapy. In its role as Core for this Program Project, the IMCPL will assume responsibility for supporting the biotherapy-based clinical trials proposed by all four projects. The Core, functioning as a GMP facility, will culture and characterize dendritic cells (DC) for patient therapy and prepare vaccines by pulsing these DC with peptides or proteins. The Core will be responsible for quality and sterility of the DC-based vaccines. It will also procure and process all body fluids and tissues harvested in the course of the clinical trials associated with this Program Project. The Core will monitor immunologic responses to the administered vaccines by performing ELISPOT assays, tetramer analyses or cytokine flow cytometry (CFC). Cytokines in supernatants or body fluids will be monitored by the immunobead-based multiplex method. The Core will also be prepared to assist the Program Project investigators in implementing assays necessary for evaluation of immunologic responses to vaccines. The Core will ensure that all cellular products it generates and samples it collects are accompanied by appropriate documentation that will permit linking laboratory analyses with clinical results. The Core will also provide assistsance in preparation of IND submissions. The Core laboratory has a long history of collaboration with all of the investigators, and in the context of this Program Project will be entirely dedicated to the support of the clinical trials for patients with head and neck cancer, melanoma or renal cell carcinoma.